Akari Therapeutics Plc Stock Price, News & Analysis

Akari Therapeutics (Nasdaq: AKTX) announced promising results for its complement and leukotriene inhibitor, nomacopan, which improved survival rates in a preclinical trauma model from 30% to 80%. Funded by the U.S. Army's DoD, the findings suggest nomacopan's potential as a treatment for traumatic hemorrhage, addressing both military and civilian needs. The company plans further studies, including a collaboration for a UK observational study on traumatic brain injury. Nomacopan targets critical inflammatory pathways, making it viable for early intervention in severe trauma cases.

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company, announced that CEO Clive Richardson will present at the BIO CEO & Investor Conference on February 15, 2022, at 2:30 p.m. ET in New York. The presentation will focus on Akari's innovative therapies targeting orphan autoimmune diseases and will be available live and on-demand for registered participants. The Company is developing Nomacopan, a C5 complement inhibitor, for conditions like bullous pemphigoid and thrombotic microangiopathy. Investors are encouraged to arrange meetings with management during the conference.

Akari Therapeutics (Nasdaq: AKTX) announced the development of an inhaled delivery system for its drug nomacopan, targeting orphan autoimmune and inflammatory diseases. Collaborating with Inhalation Sciences AB, Akari aims to enhance dosing and pharmacokinetics for both dry powder and nebulized forms. CEO Clive Richardson emphasized the potential of nomacopan in treating exacerbations in lung diseases like COPD and severe asthma by targeting complement C5 and leukotriene pathways. Observational studies show elevated levels of C5 and LTB4 in exacerbating conditions, supporting nomacopan's therapeutic potential.

Akari Therapeutics announced the FDA's approval of a new manufacturing process for its lead drug candidate, nomacopan, enhancing yield by at least 5-fold. This advancement significantly reduces the cost of goods for ongoing clinical studies and future commercialization. Nomacopan is currently in two Phase III clinical programs targeting conditions like bullous pemphigoid and thrombotic microangiopathy. This milestone marks a pivotal step towards bringing nomacopan to market, following years of development and collaboration with manufacturing partners.

Akari Therapeutics, Plc (Nasdaq: AKTX) announced that CEO Clive Richardson will present a company overview at the H.C. Wainwright BioConnect Conference, taking place virtually from January 10-13, 2022. The pre-recorded presentation will be accessible on-demand starting January 10, 2022, at 7:00 a.m. ET on the company’s website. Akari focuses on innovative therapeutics for rare autoimmune diseases, with its leading drug candidate Nomacopan targeting conditions influenced by complement and leukotriene systems.

Akari Therapeutics (Nasdaq: AKTX) announced a registered direct offering to raise approximately $6.0 million. The company will issue approximately 4,310,839 American Depository Shares (ADSs) at $1.40 per ADS, along with warrants for one-half ADS at an exercise price of $1.65. The offering is expected to close around January 4, 2022, pending customary conditions. Akari focuses on developing treatments for autoimmune and inflammatory diseases, with its lead drug candidate nomacopan currently in clinical evaluation for various conditions.

Akari Therapeutics (NASDAQ: AKTX) reported progress in its clinical programs for nomacopan, focusing on treatments for severe autoimmune conditions, including bullous pemphigoid and pediatric HSCT-TMA. The Phase III studies are now enrolling patients, with FDA designations as Orphan Drug and Fast Track. Financially, as of September 30, 2021, the company had $13.4 million in cash and reported a net loss of approximately $1.5 million for Q3 2021, compared to a net income of around $0.9 million in Q3 2020. R&D income also declined significantly to $0.4 million.

Akari Therapeutics (Nasdaq: AKTX) announces findings suggesting the therapeutic potential of nomacopan in managing exacerbations related to severe lung conditions like COPD and COVID pneumonia. Data from observational studies indicate elevated levels of inflammatory mediators C5a, C5b9, and LTB4 in patients, correlating with disease severity. The increasing evidence highlights nomacopan's ability to inhibit these mediators, potentially aiding in disease progression prevention. Akari is pursuing further clinical evaluation of inhaled nomacopan's pharmacokinetics in exacerbating patients.

Akari Therapeutics (AKTX) announces Professor Tim Higenbottam will present at the 5th Annual Complement-based Drug Development Summit from October 26-28, 2021. His presentation, titled 'Clinical Impacts of Controlling Dysregulation of the Terminal Complement Pathway and LTB4,' will focus on complement dysregulation in various diseases, insights from COVID-19, and the implications for treating these conditions with Akari’s lead candidate, Nomacopan. The presentation is scheduled for October 28 at 3:00 p.m. ET, and after, it will be accessible on Akari's website.